cancer

Overcoming T Cell Therapy Barriers with Engineered Proteins

Shannon Oda will discuss how to develop novel engineered fusion proteins to improve T cell therapies against hematological and solid tumors.

This webinar will be hosted live and available on-demand

Tuesday, September 13 2022 
2:30 PM Eastern Time (11:30 AM PT)

The tumor microenvironment can severely diminish adoptive T cell therapy efficacy by expressing ligands that activate T cell inhibitory receptors and by downregulating costimulatory ligand expression. To address these challenges, researchers developed fusion proteins (FPs) that combine the ectodomain of one receptor with a different intracellular costimulatory signaling domain. Using in vitro assays, including the Incucyte® serial killing over-time (SKO) assay, they evaluated T cell engineering strategies in persistence and survival studies.

In this LabTools webinar brought to you by Sartorius, Shannon Oda will discuss how pairing different extracellular and intracellular domains in FPs confers different attributes to therapeutic T cells.

Topics to be covered

  • Evaluating T cell function
  • Engineering strategies for enhancing T cells’ therapeutic efficacy
  • Inhibitory obstacles in the tumor microenvironment


Shannon K. Oda, PhD
Principal Investigator, Seattle Children’s Research Institute
Assistant Professor, University of Washington


Sponsored by